nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC6A4—chronic obstructive pulmonary disease	0.37	1	CbGaD
Amphetamine—SLC22A5—Tiotropium—chronic obstructive pulmonary disease	0.0986	0.222	CbGbCtD
Amphetamine—CYP2A6—Formoterol—chronic obstructive pulmonary disease	0.0842	0.189	CbGbCtD
Amphetamine—CYP2A6—Arformoterol—chronic obstructive pulmonary disease	0.0842	0.189	CbGbCtD
Amphetamine—CYP2A6—Montelukast—chronic obstructive pulmonary disease	0.0638	0.143	CbGbCtD
Amphetamine—CYP2A6—Prednisolone—chronic obstructive pulmonary disease	0.0374	0.0841	CbGbCtD
Amphetamine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0265	0.0595	CbGbCtD
Amphetamine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0265	0.0595	CbGbCtD
Amphetamine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0236	0.053	CbGbCtD
Amphetamine—TAAR1—respiratory system—chronic obstructive pulmonary disease	0.00395	0.169	CbGeAlD
Amphetamine—CARTPT—connective tissue—chronic obstructive pulmonary disease	0.00347	0.149	CbGeAlD
Amphetamine—TAAR1—lung—chronic obstructive pulmonary disease	0.0021	0.0897	CbGeAlD
Amphetamine—SLC6A3—respiratory system—chronic obstructive pulmonary disease	0.00101	0.0434	CbGeAlD
Amphetamine—SLC6A4—respiratory system—chronic obstructive pulmonary disease	0.00093	0.0398	CbGeAlD
Amphetamine—MAOB—respiratory system—chronic obstructive pulmonary disease	0.000884	0.0378	CbGeAlD
Amphetamine—SLC22A3—connective tissue—chronic obstructive pulmonary disease	0.000841	0.036	CbGeAlD
Amphetamine—SLC6A2—respiratory system—chronic obstructive pulmonary disease	0.000818	0.035	CbGeAlD
Amphetamine—MAOB—connective tissue—chronic obstructive pulmonary disease	0.000778	0.0333	CbGeAlD
Amphetamine—SLC22A3—smooth muscle tissue—chronic obstructive pulmonary disease	0.000769	0.0329	CbGeAlD
Amphetamine—DRD2—respiratory system—chronic obstructive pulmonary disease	0.000746	0.0319	CbGeAlD
Amphetamine—MAOB—bronchus—chronic obstructive pulmonary disease	0.000727	0.0311	CbGeAlD
Amphetamine—SLC18A2—lung—chronic obstructive pulmonary disease	0.000712	0.0305	CbGeAlD
Amphetamine—SLC22A5—respiratory system—chronic obstructive pulmonary disease	0.000695	0.0297	CbGeAlD
Amphetamine—CYP2A6—lung—chronic obstructive pulmonary disease	0.000636	0.0272	CbGeAlD
Amphetamine—SLC22A5—bronchus—chronic obstructive pulmonary disease	0.000572	0.0245	CbGeAlD
Amphetamine—SLC6A3—lung—chronic obstructive pulmonary disease	0.000539	0.0231	CbGeAlD
Amphetamine—Myocardial infarction—Formoterol—chronic obstructive pulmonary disease	0.000526	0.00468	CcSEcCtD
Amphetamine—Myocardial infarction—Arformoterol—chronic obstructive pulmonary disease	0.000526	0.00468	CcSEcCtD
Amphetamine—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.000522	0.00464	CcSEcCtD
Amphetamine—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.000522	0.00464	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Montelukast—chronic obstructive pulmonary disease	0.000521	0.00464	CcSEcCtD
Amphetamine—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.000516	0.00459	CcSEcCtD
Amphetamine—SLC22A5—trachea—chronic obstructive pulmonary disease	0.000513	0.022	CbGeAlD
Amphetamine—SLC22A3—lung—chronic obstructive pulmonary disease	0.000507	0.0217	CbGeAlD
Amphetamine—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.000506	0.0045	CcSEcCtD
Amphetamine—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000497	0.00442	CcSEcCtD
Amphetamine—SLC6A4—lung—chronic obstructive pulmonary disease	0.000494	0.0211	CbGeAlD
Amphetamine—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000493	0.00438	CcSEcCtD
Amphetamine—Palpitations—Aminophylline—chronic obstructive pulmonary disease	0.000487	0.00433	CcSEcCtD
Amphetamine—Sweating—Salbutamol—chronic obstructive pulmonary disease	0.000486	0.00432	CcSEcCtD
Amphetamine—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000484	0.0043	CcSEcCtD
Amphetamine—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.000477	0.00425	CcSEcCtD
Amphetamine—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.000475	0.00422	CcSEcCtD
Amphetamine—MAOB—lung—chronic obstructive pulmonary disease	0.000469	0.0201	CbGeAlD
Amphetamine—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.000468	0.00416	CcSEcCtD
Amphetamine—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.000461	0.0041	CcSEcCtD
Amphetamine—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.000459	0.00408	CcSEcCtD
Amphetamine—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.00045	0.004	CcSEcCtD
Amphetamine—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000449	0.00399	CcSEcCtD
Amphetamine—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000447	0.00397	CcSEcCtD
Amphetamine—Euphoric mood—Prednisolone—chronic obstructive pulmonary disease	0.000446	0.00397	CcSEcCtD
Amphetamine—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.000446	0.00397	CcSEcCtD
Amphetamine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000446	0.00397	CcSEcCtD
Amphetamine—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.000442	0.00393	CcSEcCtD
Amphetamine—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.000439	0.0039	CcSEcCtD
Amphetamine—SLC6A2—lung—chronic obstructive pulmonary disease	0.000435	0.0186	CbGeAlD
Amphetamine—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000433	0.00385	CcSEcCtD
Amphetamine—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000429	0.00381	CcSEcCtD
Amphetamine—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.000429	0.00381	CcSEcCtD
Amphetamine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000425	0.00378	CcSEcCtD
Amphetamine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000425	0.00378	CcSEcCtD
Amphetamine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000423	0.00376	CcSEcCtD
Amphetamine—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000421	0.00375	CcSEcCtD
Amphetamine—Viral infection—Prednisone—chronic obstructive pulmonary disease	0.000418	0.00372	CcSEcCtD
Amphetamine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000414	0.00368	CcSEcCtD
Amphetamine—Tension—Formoterol—chronic obstructive pulmonary disease	0.000412	0.00366	CcSEcCtD
Amphetamine—Tension—Arformoterol—chronic obstructive pulmonary disease	0.000412	0.00366	CcSEcCtD
Amphetamine—Injury—Prednisolone—chronic obstructive pulmonary disease	0.00041	0.00365	CcSEcCtD
Amphetamine—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000407	0.00362	CcSEcCtD
Amphetamine—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000407	0.00362	CcSEcCtD
Amphetamine—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000407	0.00362	CcSEcCtD
Amphetamine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000401	0.00356	CcSEcCtD
Amphetamine—DRD2—lung—chronic obstructive pulmonary disease	0.000396	0.017	CbGeAlD
Amphetamine—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000396	0.00352	CcSEcCtD
Amphetamine—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000393	0.00349	CcSEcCtD
Amphetamine—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000393	0.00349	CcSEcCtD
Amphetamine—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000391	0.00348	CcSEcCtD
Amphetamine—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000389	0.00346	CcSEcCtD
Amphetamine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000385	0.00343	CcSEcCtD
Amphetamine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000385	0.00343	CcSEcCtD
Amphetamine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000385	0.00342	CcSEcCtD
Amphetamine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000385	0.00342	CcSEcCtD
Amphetamine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000384	0.00341	CcSEcCtD
Amphetamine—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.000383	0.00341	CcSEcCtD
Amphetamine—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.000383	0.00341	CcSEcCtD
Amphetamine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000378	0.00336	CcSEcCtD
Amphetamine—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.000375	0.00334	CcSEcCtD
Amphetamine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000373	0.00332	CcSEcCtD
Amphetamine—Affect lability—Prednisolone—chronic obstructive pulmonary disease	0.000371	0.0033	CcSEcCtD
Amphetamine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000371	0.0033	CcSEcCtD
Amphetamine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000371	0.0033	CcSEcCtD
Amphetamine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000371	0.0033	CcSEcCtD
Amphetamine—SLC22A5—lung—chronic obstructive pulmonary disease	0.000369	0.0158	CbGeAlD
Amphetamine—Ephedrine—ADRB2—chronic obstructive pulmonary disease	0.000368	0.101	CrCbGaD
Amphetamine—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000368	0.00327	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000366	0.00326	CcSEcCtD
Amphetamine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000364	0.00324	CcSEcCtD
Amphetamine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000363	0.00323	CcSEcCtD
Amphetamine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000363	0.00323	CcSEcCtD
Amphetamine—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000362	0.00322	CcSEcCtD
Amphetamine—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000362	0.00322	CcSEcCtD
Amphetamine—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000362	0.00322	CcSEcCtD
Amphetamine—Mood swings—Prednisolone—chronic obstructive pulmonary disease	0.000357	0.00318	CcSEcCtD
Amphetamine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000357	0.00318	CcSEcCtD
Amphetamine—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000357	0.00318	CcSEcCtD
Amphetamine—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000357	0.00318	CcSEcCtD
Amphetamine—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000356	0.00317	CcSEcCtD
Amphetamine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000356	0.00316	CcSEcCtD
Amphetamine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000356	0.00316	CcSEcCtD
Amphetamine—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000356	0.00316	CcSEcCtD
Amphetamine—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000356	0.00316	CcSEcCtD
Amphetamine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00035	0.00311	CcSEcCtD
Amphetamine—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000349	0.00311	CcSEcCtD
Amphetamine—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000349	0.00311	CcSEcCtD
Amphetamine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000349	0.0031	CcSEcCtD
Amphetamine—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000347	0.00308	CcSEcCtD
Amphetamine—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000342	0.00304	CcSEcCtD
Amphetamine—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000342	0.00304	CcSEcCtD
Amphetamine—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000342	0.00304	CcSEcCtD
Amphetamine—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00034	0.00302	CcSEcCtD
Amphetamine—Infection—Formoterol—chronic obstructive pulmonary disease	0.00034	0.00302	CcSEcCtD
Amphetamine—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000337	0.003	CcSEcCtD
Amphetamine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000337	0.003	CcSEcCtD
Amphetamine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000336	0.00299	CcSEcCtD
Amphetamine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000335	0.00298	CcSEcCtD
Amphetamine—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000335	0.00298	CcSEcCtD
Amphetamine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000334	0.00297	CcSEcCtD
Amphetamine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000334	0.00297	CcSEcCtD
Amphetamine—Infection—Montelukast—chronic obstructive pulmonary disease	0.000333	0.00296	CcSEcCtD
Amphetamine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000331	0.00295	CcSEcCtD
Amphetamine—Phenylpropanolamine—ADRB2—chronic obstructive pulmonary disease	0.00033	0.091	CrCbGaD
Amphetamine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00033	0.00293	CcSEcCtD
Amphetamine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000324	0.00289	CcSEcCtD
Amphetamine—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000323	0.00287	CcSEcCtD
Amphetamine—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000321	0.00286	CcSEcCtD
Amphetamine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000315	0.00281	CcSEcCtD
Amphetamine—Pseudoephedrine—TNF—chronic obstructive pulmonary disease	0.000315	0.0867	CrCbGaD
Amphetamine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000312	0.00278	CcSEcCtD
Amphetamine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000312	0.00278	CcSEcCtD
Amphetamine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00031	0.00275	CcSEcCtD
Amphetamine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00031	0.00275	CcSEcCtD
Amphetamine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000308	0.00274	CcSEcCtD
Amphetamine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000308	0.00274	CcSEcCtD
Amphetamine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000305	0.00271	CcSEcCtD
Amphetamine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000305	0.00271	CcSEcCtD
Amphetamine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000304	0.00271	CcSEcCtD
Amphetamine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000304	0.00271	CcSEcCtD
Amphetamine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000303	0.0027	CcSEcCtD
Amphetamine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000301	0.00268	CcSEcCtD
Amphetamine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000301	0.00268	CcSEcCtD
Amphetamine—Injury—Prednisone—chronic obstructive pulmonary disease	0.000298	0.00265	CcSEcCtD
Amphetamine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000298	0.00265	CcSEcCtD
Amphetamine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000297	0.00265	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000296	0.00263	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000296	0.00263	CcSEcCtD
Amphetamine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000295	0.00262	CcSEcCtD
Amphetamine—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000295	0.00262	CcSEcCtD
Amphetamine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000295	0.00262	CcSEcCtD
Amphetamine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000293	0.0026	CcSEcCtD
Amphetamine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000293	0.0026	CcSEcCtD
Amphetamine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000292	0.0026	CcSEcCtD
Amphetamine—Tranylcypromine—CYP1A2—chronic obstructive pulmonary disease	0.00029	0.08	CrCbGaD
Amphetamine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000289	0.00257	CcSEcCtD
Amphetamine—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000289	0.00257	CcSEcCtD
Amphetamine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.00256	CcSEcCtD
Amphetamine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000287	0.00256	CcSEcCtD
Amphetamine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000287	0.00255	CcSEcCtD
Amphetamine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000286	0.00254	CcSEcCtD
Amphetamine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000285	0.00253	CcSEcCtD
Amphetamine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000285	0.00253	CcSEcCtD
Amphetamine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000284	0.00252	CcSEcCtD
Amphetamine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000283	0.00252	CcSEcCtD
Amphetamine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000282	0.00251	CcSEcCtD
Amphetamine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000281	0.0025	CcSEcCtD
Amphetamine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00028	0.00249	CcSEcCtD
Amphetamine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00028	0.00249	CcSEcCtD
Amphetamine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00028	0.00249	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000279	0.00248	CcSEcCtD
Amphetamine—Pseudoephedrine—ADRB2—chronic obstructive pulmonary disease	0.000279	0.0769	CrCbGaD
Amphetamine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000279	0.00248	CcSEcCtD
Amphetamine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000276	0.00246	CcSEcCtD
Amphetamine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000274	0.00244	CcSEcCtD
Amphetamine—Phenylpropanolamine—CYP1A2—chronic obstructive pulmonary disease	0.000273	0.0752	CrCbGaD
Amphetamine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000272	0.00242	CcSEcCtD
Amphetamine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000272	0.00242	CcSEcCtD
Amphetamine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000271	0.00241	CcSEcCtD
Amphetamine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000271	0.00241	CcSEcCtD
Amphetamine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000271	0.00241	CcSEcCtD
Amphetamine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000271	0.00241	CcSEcCtD
Amphetamine—Affect lability—Prednisone—chronic obstructive pulmonary disease	0.00027	0.0024	CcSEcCtD
Amphetamine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00027	0.0024	CcSEcCtD
Amphetamine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000268	0.00238	CcSEcCtD
Amphetamine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000267	0.00238	CcSEcCtD
Amphetamine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000267	0.00238	CcSEcCtD
Amphetamine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000267	0.00238	CcSEcCtD
Amphetamine—Phentermine—SLC6A4—chronic obstructive pulmonary disease	0.000267	0.0736	CrCbGaD
Amphetamine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000266	0.00237	CcSEcCtD
Amphetamine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000266	0.00236	CcSEcCtD
Amphetamine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000265	0.00236	CcSEcCtD
Amphetamine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000265	0.00236	CcSEcCtD
Amphetamine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000264	0.00235	CcSEcCtD
Amphetamine—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000262	0.00233	CcSEcCtD
Amphetamine—Mood swings—Prednisone—chronic obstructive pulmonary disease	0.00026	0.00231	CcSEcCtD
Amphetamine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000257	0.00228	CcSEcCtD
Amphetamine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00227	CcSEcCtD
Amphetamine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00227	CcSEcCtD
Amphetamine—Pseudoephedrine—SLC6A4—chronic obstructive pulmonary disease	0.000253	0.0698	CrCbGaD
Amphetamine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000252	0.00224	CcSEcCtD
Amphetamine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000252	0.00224	CcSEcCtD
Amphetamine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000252	0.00224	CcSEcCtD
Amphetamine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000247	0.0022	CcSEcCtD
Amphetamine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000246	0.00218	CcSEcCtD
Amphetamine—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000246	0.00218	CcSEcCtD
Amphetamine—Phentermine—CYP1A2—chronic obstructive pulmonary disease	0.000243	0.0671	CrCbGaD
Amphetamine—Benzyl alcohol—CYP1A1—chronic obstructive pulmonary disease	0.000243	0.0671	CrCbGaD
Amphetamine—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000241	0.00214	CcSEcCtD
Amphetamine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000238	0.00212	CcSEcCtD
Amphetamine—Benzyl alcohol—CYP1A2—chronic obstructive pulmonary disease	0.000235	0.0647	CrCbGaD
Amphetamine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000234	0.00208	CcSEcCtD
Amphetamine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000234	0.00208	CcSEcCtD
Amphetamine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000232	0.00206	CcSEcCtD
Amphetamine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000229	0.00204	CcSEcCtD
Amphetamine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000226	0.00201	CcSEcCtD
Amphetamine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000226	0.00201	CcSEcCtD
Amphetamine—Selegiline—CYP1A2—chronic obstructive pulmonary disease	0.000225	0.062	CrCbGaD
Amphetamine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000222	0.00197	CcSEcCtD
Amphetamine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000221	0.00197	CcSEcCtD
Amphetamine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000218	0.00194	CcSEcCtD
Amphetamine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000218	0.00194	CcSEcCtD
Amphetamine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.00194	CcSEcCtD
Amphetamine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.00192	CcSEcCtD
Amphetamine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000216	0.00192	CcSEcCtD
Amphetamine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000216	0.00192	CcSEcCtD
Amphetamine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000216	0.00192	CcSEcCtD
Amphetamine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000214	0.00191	CcSEcCtD
Amphetamine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000214	0.00191	CcSEcCtD
Amphetamine—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000214	0.00191	CcSEcCtD
Amphetamine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000214	0.0019	CcSEcCtD
Amphetamine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000213	0.0019	CcSEcCtD
Amphetamine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000211	0.00188	CcSEcCtD
Amphetamine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000211	0.00188	CcSEcCtD
Amphetamine—Depression—Prednisone—chronic obstructive pulmonary disease	0.000211	0.00187	CcSEcCtD
Amphetamine—Headache—Montelukast—chronic obstructive pulmonary disease	0.00021	0.00187	CcSEcCtD
Amphetamine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000208	0.00185	CcSEcCtD
Amphetamine—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000208	0.00185	CcSEcCtD
Amphetamine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000207	0.00184	CcSEcCtD
Amphetamine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.00183	CcSEcCtD
Amphetamine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.00181	CcSEcCtD
Amphetamine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000204	0.00181	CcSEcCtD
Amphetamine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000203	0.00181	CcSEcCtD
Amphetamine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000203	0.00181	CcSEcCtD
Amphetamine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000202	0.0018	CcSEcCtD
Amphetamine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000199	0.00177	CcSEcCtD
Amphetamine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000197	0.00175	CcSEcCtD
Amphetamine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000196	0.00174	CcSEcCtD
Amphetamine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000192	0.00171	CcSEcCtD
Amphetamine—Methamphetamine—SLC6A4—chronic obstructive pulmonary disease	0.00019	0.0525	CrCbGaD
Amphetamine—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000185	0.00165	CcSEcCtD
Amphetamine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000181	0.00161	CcSEcCtD
Amphetamine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000179	0.00159	CcSEcCtD
Amphetamine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000168	0.00149	CcSEcCtD
Amphetamine—SLC6A3—Monoamine Transport—IL1B—chronic obstructive pulmonary disease	0.000164	0.00355	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000164	0.00354	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000163	0.00352	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000163	0.00352	CbGpPWpGaD
Amphetamine—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.00016	0.00347	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000158	0.00341	CbGpPWpGaD
Amphetamine—SLC6A4—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000156	0.00338	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000154	0.00333	CbGpPWpGaD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000154	0.00332	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000152	0.00329	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000152	0.00329	CbGpPWpGaD
Amphetamine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000152	0.00135	CcSEcCtD
Amphetamine—SLC6A2—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000151	0.00327	CbGpPWpGaD
Amphetamine—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000151	0.00134	CcSEcCtD
Amphetamine—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.00015	0.00325	CbGpPWpGaD
Amphetamine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.00015	0.00324	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.00015	0.00324	CbGpPWpGaD
Amphetamine—CYP2A6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000148	0.0032	CbGpPWpGaD
Amphetamine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000147	0.00131	CcSEcCtD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000145	0.00314	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.000144	0.00312	CbGpPWpGaD
Amphetamine—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000143	0.00127	CcSEcCtD
Amphetamine—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000143	0.00127	CcSEcCtD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.00014	0.00303	CbGpPWpGaD
Amphetamine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.00014	0.00125	CcSEcCtD
Amphetamine—MAOB—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.00014	0.00302	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000137	0.00295	CbGpPWpGaD
Amphetamine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000137	0.00121	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000135	0.00292	CbGpPWpGaD
Amphetamine—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000135	0.0012	CcSEcCtD
Amphetamine—SLC6A2—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000134	0.00291	CbGpPWpGaD
Amphetamine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—chronic obstructive pulmonary disease	0.000134	0.0029	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000134	0.0029	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000134	0.00289	CbGpPWpGaD
Amphetamine—Infection—Prednisone—chronic obstructive pulmonary disease	0.000134	0.00119	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000133	0.00287	CbGpPWpGaD
Amphetamine—MAOB—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000132	0.00286	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000132	0.00285	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	0.000132	0.00285	CbGpPWpGaD
Amphetamine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000131	0.00117	CcSEcCtD
Amphetamine—SLC6A4—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000131	0.00283	CbGpPWpGaD
Amphetamine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.00013	0.00116	CcSEcCtD
Amphetamine—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000128	0.00114	CcSEcCtD
Amphetamine—SLC6A4—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	0.000125	0.0027	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	0.000125	0.00269	CbGpPWpGaD
Amphetamine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000123	0.00109	CcSEcCtD
Amphetamine—TAAR1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000123	0.00265	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000122	0.00264	CbGpPWpGaD
Amphetamine—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000122	0.00108	CcSEcCtD
Amphetamine—CYP2A6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000121	0.00263	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	0.00012	0.0026	CbGpPWpGaD
Amphetamine—SLC6A3—Monoamine Transport—TNF—chronic obstructive pulmonary disease	0.000119	0.00257	CbGpPWpGaD
Amphetamine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000119	0.00105	CcSEcCtD
Amphetamine—TAAR1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000119	0.00256	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000118	0.00256	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000117	0.00253	CbGpPWpGaD
Amphetamine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000117	0.00104	CcSEcCtD
Amphetamine—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.00104	CcSEcCtD
Amphetamine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000117	0.00104	CcSEcCtD
Amphetamine—Nateglinide—ALB—chronic obstructive pulmonary disease	0.000116	0.032	CrCbGaD
Amphetamine—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000116	0.00103	CcSEcCtD
Amphetamine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.00103	CcSEcCtD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000116	0.0025	CbGpPWpGaD
Amphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000116	0.0025	CbGpPWpGaD
Amphetamine—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000115	0.00102	CcSEcCtD
Amphetamine—CYP2A6—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	0.000114	0.00247	CbGpPWpGaD
Amphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000114	0.00247	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000114	0.00247	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	0.000113	0.00243	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	0.000112	0.00242	CbGpPWpGaD
Amphetamine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.00011	0.00098	CcSEcCtD
Amphetamine—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.00011	0.000979	CcSEcCtD
Amphetamine—SLC6A3—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000107	0.00232	CbGpPWpGaD
Amphetamine—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000952	CcSEcCtD
Amphetamine—CYP2A6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000107	0.00231	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APIP—chronic obstructive pulmonary disease	0.000107	0.0023	CbGpPWpGaD
Amphetamine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000947	CcSEcCtD
Amphetamine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000947	CcSEcCtD
Amphetamine—CYP2A6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000106	0.00228	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	0.000105	0.00227	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000102	0.00221	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	0.000101	0.00218	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	9.97e-05	0.00215	CbGpPWpGaD
Amphetamine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	9.93e-05	0.000883	CcSEcCtD
Amphetamine—Asthenia—Prednisone—chronic obstructive pulmonary disease	9.67e-05	0.00086	CcSEcCtD
Amphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	9.5e-05	0.00205	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	9.38e-05	0.00203	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	9.29e-05	0.00201	CbGpPWpGaD
Amphetamine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	9.22e-05	0.00082	CcSEcCtD
Amphetamine—DRD2—G alpha (i) signalling events—CXCR2—chronic obstructive pulmonary disease	9.2e-05	0.00199	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APIP—chronic obstructive pulmonary disease	9.02e-05	0.00195	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	8.98e-05	0.00194	CbGpPWpGaD
Amphetamine—Dizziness—Prednisone—chronic obstructive pulmonary disease	8.91e-05	0.000792	CcSEcCtD
Amphetamine—CYP2A6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	8.88e-05	0.00192	CbGpPWpGaD
Amphetamine—Vomiting—Prednisone—chronic obstructive pulmonary disease	8.57e-05	0.000762	CcSEcCtD
Amphetamine—CYP2A6—Fluoropyrimidine Activity—TP53—chronic obstructive pulmonary disease	8.56e-05	0.00185	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	8.54e-05	0.00185	CbGpPWpGaD
Amphetamine—Rash—Prednisone—chronic obstructive pulmonary disease	8.49e-05	0.000755	CcSEcCtD
Amphetamine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	8.49e-05	0.000755	CcSEcCtD
Amphetamine—TAAR1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	8.47e-05	0.00183	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	8.45e-05	0.00183	CbGpPWpGaD
Amphetamine—Headache—Prednisone—chronic obstructive pulmonary disease	8.44e-05	0.000751	CcSEcCtD
Amphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	8.4e-05	0.00182	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—SLC6A4—chronic obstructive pulmonary disease	8.34e-05	0.0018	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	8.33e-05	0.0018	CbGpPWpGaD
Amphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	8.29e-05	0.00179	CbGpPWpGaD
Amphetamine—Nausea—Prednisone—chronic obstructive pulmonary disease	8e-05	0.000712	CcSEcCtD
Amphetamine—SLC6A4—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	7.77e-05	0.00168	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	7.76e-05	0.00168	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	7.69e-05	0.00166	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—ADIPOQ—chronic obstructive pulmonary disease	7.65e-05	0.00165	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—HDAC2—chronic obstructive pulmonary disease	7.62e-05	0.00165	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	7.57e-05	0.00164	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.41e-05	0.0016	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	7.32e-05	0.00158	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	7.24e-05	0.00156	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	7.24e-05	0.00156	CbGpPWpGaD
Amphetamine—TAAR1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	7.24e-05	0.00156	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.06e-05	0.00153	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	6.87e-05	0.00149	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GC—chronic obstructive pulmonary disease	6.87e-05	0.00148	CbGpPWpGaD
Amphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	6.81e-05	0.00147	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.81e-05	0.00147	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	6.62e-05	0.00143	CbGpPWpGaD
Amphetamine—CYP2A6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.45e-05	0.00139	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	6.38e-05	0.00138	CbGpPWpGaD
Amphetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	6.33e-05	0.00137	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	6.32e-05	0.00137	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	6.1e-05	0.00132	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	6.07e-05	0.00131	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	6.01e-05	0.0013	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.99e-05	0.0013	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.97e-05	0.00129	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	5.92e-05	0.00128	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GC—chronic obstructive pulmonary disease	5.81e-05	0.00126	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	5.57e-05	0.0012	CbGpPWpGaD
Amphetamine—SLC22A3—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	5.47e-05	0.00118	CbGpPWpGaD
Amphetamine—SLC22A5—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	5.46e-05	0.00118	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.4e-05	0.00117	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	5.36e-05	0.00116	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	5.36e-05	0.00116	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	5.29e-05	0.00114	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APIP—chronic obstructive pulmonary disease	5.19e-05	0.00112	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	5.14e-05	0.00111	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.98e-05	0.00108	CbGpPWpGaD
Amphetamine—SLC6A4—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	4.97e-05	0.00107	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	4.92e-05	0.00106	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.91e-05	0.00106	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	4.75e-05	0.00103	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	4.63e-05	0.001	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	4.62e-05	0.000998	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	4.59e-05	0.000992	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	4.56e-05	0.000986	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.54e-05	0.000982	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	4.43e-05	0.000957	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	4.4e-05	0.000951	CbGpPWpGaD
Amphetamine—SLC6A2—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	4.27e-05	0.000924	CbGpPWpGaD
Amphetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	4.26e-05	0.00092	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	4.19e-05	0.000905	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.15e-05	0.000898	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	4.1e-05	0.000886	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.1e-05	0.000885	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	4.09e-05	0.000884	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.06e-05	0.000877	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	3.91e-05	0.000844	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.82e-05	0.000825	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.79e-05	0.000818	CbGpPWpGaD
Amphetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	3.77e-05	0.000815	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.76e-05	0.000814	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.75e-05	0.000811	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	3.73e-05	0.000806	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.71e-05	0.000803	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GCLC—chronic obstructive pulmonary disease	3.71e-05	0.000801	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.69e-05	0.000797	CbGpPWpGaD
Amphetamine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.62e-05	0.000782	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.6e-05	0.000779	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	3.59e-05	0.000775	CbGpPWpGaD
Amphetamine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.57e-05	0.000771	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	3.55e-05	0.000768	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.55e-05	0.000767	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	3.55e-05	0.000766	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	3.49e-05	0.000755	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.44e-05	0.000743	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CTGF—chronic obstructive pulmonary disease	3.38e-05	0.000731	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GC—chronic obstructive pulmonary disease	3.35e-05	0.000723	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.3e-05	0.000713	CbGpPWpGaD
Amphetamine—SLC18A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.22e-05	0.000695	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	3.19e-05	0.00069	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.17e-05	0.000686	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	3.17e-05	0.000685	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	3.16e-05	0.000684	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.15e-05	0.00068	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GCLC—chronic obstructive pulmonary disease	3.14e-05	0.000678	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.12e-05	0.000675	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.12e-05	0.000674	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.11e-05	0.000672	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	2.91e-05	0.000629	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	2.9e-05	0.000627	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CTGF—chronic obstructive pulmonary disease	2.86e-05	0.000619	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.86e-05	0.000618	CbGpPWpGaD
Amphetamine—DRD2—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	2.79e-05	0.000602	CbGpPWpGaD
Amphetamine—SLC22A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.78e-05	0.000601	CbGpPWpGaD
Amphetamine—SLC22A5—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.77e-05	0.000599	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.76e-05	0.000597	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.73e-05	0.00059	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.71e-05	0.000587	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.64e-05	0.00057	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.6e-05	0.000562	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.59e-05	0.00056	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.56e-05	0.000554	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.47e-05	0.000534	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.39e-05	0.000516	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.27e-05	0.00049	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.22e-05	0.000479	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.2e-05	0.000475	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.19e-05	0.000474	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.17e-05	0.000469	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.16e-05	0.000468	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.1e-05	0.000453	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.09e-05	0.000451	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.02e-05	0.000437	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.98e-05	0.000429	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.97e-05	0.000427	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	1.94e-05	0.000419	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.93e-05	0.000417	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.92e-05	0.000414	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.92e-05	0.000414	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	1.88e-05	0.000405	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.83e-05	0.000395	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.81e-05	0.00039	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.79e-05	0.000388	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.78e-05	0.000385	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	1.77e-05	0.000383	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.76e-05	0.000381	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.74e-05	0.000377	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.69e-05	0.000365	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.69e-05	0.000365	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.65e-05	0.000356	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.64e-05	0.000353	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.6e-05	0.000347	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.6e-05	0.000346	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.54e-05	0.000334	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ALB—chronic obstructive pulmonary disease	1.54e-05	0.000333	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.52e-05	0.000328	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NOS3—chronic obstructive pulmonary disease	1.47e-05	0.000318	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.4e-05	0.000303	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.35e-05	0.000291	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ALB—chronic obstructive pulmonary disease	1.3e-05	0.000282	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.27e-05	0.000274	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.25e-05	0.00027	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NOS3—chronic obstructive pulmonary disease	1.25e-05	0.000269	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.23e-05	0.000267	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.23e-05	0.000266	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.16e-05	0.000252	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.15e-05	0.000248	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.1e-05	0.000238	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.06e-05	0.000229	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.02e-05	0.000221	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.01e-05	0.000219	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	9.54e-06	0.000206	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	9.47e-06	0.000205	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	9.24e-06	0.0002	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	8.66e-06	0.000187	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	8.61e-06	0.000186	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.52e-06	0.000184	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	8.28e-06	0.000179	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	7.7e-06	0.000166	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALB—chronic obstructive pulmonary disease	7.5e-06	0.000162	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NOS3—chronic obstructive pulmonary disease	7.18e-06	0.000155	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.1e-06	0.000154	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.01e-06	0.000151	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.53e-06	0.000141	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	6.33e-06	0.000137	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.19e-06	0.000134	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	6.04e-06	0.000131	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.77e-06	0.000125	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	5.12e-06	0.000111	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.87e-06	0.000105	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.63e-06	0.0001	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	4.21e-06	9.09e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	4.16e-06	8.98e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	4.02e-06	8.7e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.81e-06	8.24e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.74e-06	8.08e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.14e-06	6.79e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.87e-06	6.21e-05	CbGpPWpGaD
